Literature DB >> 1362461

Cryptosporidiosis in HIV-seropositive patients.

C Blanshard1, A M Jackson, D C Shanson, N Francis, B G Gazzard.   

Abstract

The incidence of cryptosporidiosis in our unit has increased over the last 6 years, being diagnosed in approximately 5 per cent of all patients with HIV infection and in 21 per cent of those with AIDS, but a marked seasonal variation occurs. We have studied the course of the infection in 128 patients and identified four clinical patterns of disease: transient (28.7 per cent), chronic (59.7 per cent), fulminant (7.8 per cent) and asymptomatic (3.9 per cent). Transient disease occurred in patients with a wide range of CD4 lymphocyte counts, but was more common in less immunosuppressed patients. Fulminant disease, defined by the passage of more than 2 l of stool/day from the time of presentation, only occurred in patients with a CD4 count less than 50/mm3. This group had lost more than 7 kg in weight at presentation and more commonly had other intercurrent gastrointestinal infections. They survived for a median of only 5 weeks, compared with 20 weeks for those with chronic diarrhoea and 36 weeks for those with transient infection. The survival was unaffected by any treatment other than zidovudine. Cryptosporidiosis in HIV-infected individuals is a heterogeneous disease.

Entities:  

Mesh:

Year:  1992        PMID: 1362461

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  25 in total

1.  Epidemiology of cryptosporidiosis among European AIDS patients.

Authors:  C Pedersen; S Danner; A Lazzarin; M P Glauser; R Weber; C Katlama; S E Barton; J D Lundgren
Journal:  Genitourin Med       Date:  1996-04

Review 2.  Intestinal immune response to human Cryptosporidium sp. infection.

Authors:  Birte Pantenburg; Sara M Dann; Heuy-Ching Wang; Prema Robinson; Alejandro Castellanos-Gonzalez; Dorothy E Lewis; A Clinton White
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

3.  Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients.

Authors:  C Blanshard; N Francis; B G Gazzard
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

4.  Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells.

Authors:  Birte Pantenburg; Alejandro Castellanos-Gonzalez; Sara M Dann; Rhykka L Connelly; Dorothy E Lewis; Honorine D Ward; A Clinton White
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 5.  Parasitic colitis.

Authors:  Elizabeth M Hechenbleikner; Jennifer A McQuade
Journal:  Clin Colon Rectal Surg       Date:  2015-06

Review 6.  Challenges in understanding the immunopathogenesis of Cryptosporidium infections in humans.

Authors:  R J Kothavade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

7.  Fulminant cryptosporidiosis after near-drowning: a human Cryptosporidium parvum strain implicated in invasive gastrointestinal adenocarcinoma and cholangiocarcinoma in an experimental model.

Authors:  Gabriela Certad; Sadia Benamrouz; Karine Guyot; Anthony Mouray; Thierry Chassat; Nicolas Flament; Laurence Delhaes; Valerie Coiteux; Baptiste Delaire; Marleen Praet; Claude Cuvelier; Pierre Gosset; Eduardo Dei-Cas; Colette Creusy
Journal:  Appl Environ Microbiol       Date:  2012-01-13       Impact factor: 4.792

8.  Parasitic colitides.

Authors:  Joel E Goldberg
Journal:  Clin Colon Rectal Surg       Date:  2007-02

9.  Evaluation of a screening test for detection of giardia and cryptosporidium parasites.

Authors:  Sojin Youn; Mamun Kabir; Rashidul Haque; William A Petri
Journal:  J Clin Microbiol       Date:  2008-12-03       Impact factor: 5.948

10.  Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins.

Authors:  Maria Angeles Gomez Morales; Raffaella Mele; Alessandra Ludovisi; Fabrizio Bruschi; Fabio Tosini; Rachele Riganò; Edoardo Pozio
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.